Stock Events

Stock Events

Nektar Therapeutics 

$36.78
92
+$0.00+0%Friday 01:03

Statistics

Day High
36.78
Day Low
36.78
52W High
86.13
52W Low
36.78
Volume
7
Avg. Volume
-
Mkt Cap
1.26B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 12Expected
Q3 2025
Q1 2026
Q2 2026
Next
-2.68
-2.2
-1.71
-1.23
Expected EPS
-2.069263
Actual EPS
N/A

Financials

-297.07%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
55.23MRevenue
-164.08MNet Income

Analyst Ratings

$116.29Average Price Target
The highest estimate is ⁦185.00⁩.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NKTR.BOATS. It's not an investment recommendation.
NVIDIA
23
NVDA
Microsoft
18
MSFT
Palantir Technologies
18
PLTR
Apple
15
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb competes in the oncology and immunology sectors, directly challenging Nektar's therapeutic areas.
Merck
MRK
Mkt Cap368.89B
Merck is a leader in developing cancer treatments, including immunotherapy drugs that compete with Nektar's pipeline.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad portfolio of drugs in oncology and immunology, making it a direct competitor to Nektar Therapeutics.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences focuses on innovative therapies in areas like oncology, directly competing with Nektar's research and development focus.
AMGEN
AMGN
Mkt Cap251.94B
Amgen's focus on novel therapeutics in oncology and inflammation puts it in direct competition with Nektar Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on immunology and oncology, similar to Nektar's interests.
Incyte
INCY
Mkt Cap24.54B
Incyte Corporation specializes in oncology and inflammation, competing with Nektar in the development of cancer and autoimmune disease treatments.
Biogen
BIIB
Mkt Cap37.49B
Biogen's focus on novel therapies, including work in immunology, places it as a competitor to Nektar Therapeutics.
Exelixis
EXEL
Mkt Cap16.93B
Exelixis is focused on developing small molecule therapies for cancer, directly competing with Nektar's oncology pipeline.

About

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Show More
CEO
ISIN
US6402683063

Listings

F
DE
ITH0.F
XETRA
DE
ITH0.XETRA
XNAS
US
NKTR
STU
DE
ITH0.STU

0 Comments

Share your thoughts

FAQs

What is Nektar Therapeutics stock price today?▼
The current price of NKTR.BOATS is $36.78 USD — it has increased by +0% in the past 24 hours. Watch Nektar Therapeutics stock price performance more closely on the chart.
What is Nektar Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Nektar Therapeutics stocks are traded under the ticker NKTR.BOATS.
What is Nektar Therapeutics market cap?▼
Today Nektar Therapeutics has the market capitalization of 1.26B
When is the next Nektar Therapeutics earnings date?▼
Nektar Therapeutics is going to release the next earnings report on November 12, 2026.
What were Nektar Therapeutics earnings last quarter?▼
NKTR.BOATS earnings for the last quarter are -1.23 USD per share, whereas the estimation was -1.97 USD resulting in a +37.6% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nektar Therapeutics revenue for the last year?▼
Nektar Therapeutics revenue for the last year amounts to 55.23M USD.
What is Nektar Therapeutics net income for the last year?▼
NKTR.BOATS net income for the last year is -164.08M USD.
In which sector is Nektar Therapeutics located?▼
Nektar Therapeutics operates in the Other sector.
When did Nektar Therapeutics complete a stock split?▼
The last stock split for Nektar Therapeutics was on June 9, 2025 with a ratio of 1:15.